Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC-K76 + Tislelizumab + ADT in mCRPC
NCT07389187Phase 1Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Dietary Supplement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LC-K76 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Incidence of Adverse Events at 48 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
LC-K76
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07389187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389187.